Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06592261 · ClinicalTrials.gov registry record · Phase 1
Graded Insulin Suppression Test P&F
A Phase 1 study of Healthy and Obesity, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06592261: Recruiting Phase 1 study of Healthy and Obesity, sponsored by Columbia University.
NCT06592261 is a Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by Columbia University. The registered enrollment target is 15 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06592261, a Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit in which they will undergo a "graded insulin suppression test" ("GIST"). The GIST involves intravenous (into the vein) infusions of octreotide, a medication that turns off the body's own production of insulin, as well as replacement of insulin at two different levels (low and high), with or without replacement of glucagon, and glucose (sugar). The study investigators will check blood sugar levels every few minutes during the procedure to determine the effect of the two different insulin levels. This study will evaluate the GIST in both healthy volunteers and those at higher risk for type 2 diabetes.
Primary Outcome
Plasma glucose level at steady state while insulin infusion rate is 2 mU/m2/min (units: mg/dL)
Conditions Studied
Interventions
- DRUG Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
- DRUG Insulin regular, 32 mU/m2/min (hyperinsulinemia)
- DRUG Octreotide Acetate, 6-45 ng/kg/min
- DRUG Dextrose 20 % in Water
- DRUG Glucagon, 0-0.5 ng/kg/min
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What NCT06592261 shows while recruiting
NCT06592261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia) is the first listed.
NCT06592261 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06592261 about?
NCT06592261 is a clinical study titled "Graded Insulin Suppression Test P&F". The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit ...
What is the current status of trial NCT06592261?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-09-16. Estimated completion is 2026-08.
What conditions does trial NCT06592261 study?
This clinical trial studies the following conditions: Healthy, Obesity, Insulin Resistance, Hyperinsulinemia.
What interventions are being tested in trial NCT06592261?
The interventions under investigation include: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia) (DRUG), Insulin regular, 32 mU/m2/min (hyperinsulinemia) (DRUG), Octreotide Acetate, 6-45 ng/kg/min (DRUG), Dextrose 20 % in Water (DRUG), Glucagon, 0-0.5 ng/kg/min (DRUG).
Who is sponsoring clinical trial NCT06592261?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06592261 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06592261's enrollment target sits among peer trials
15 955th of 1090 higher than 118 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI